



## I. Skin Cancers

### a. Epidemiologic/Correlative

**UCI 09-17** Biology of Human Melanocytes and Keratinocytes (Meyskens)

**UCI 14-25** Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

**UCI 16-01** ~~-Suspended-~~ (PAINT)-Pathway Analyses for Individualized Network Therapeutics for Cancer (Nelson)

### b. Prevention

**UCI 14-92** Phase IV Study of Daylight Photodynamic Therapy with Aminolevulinic Acid for Actinic Keratoses (Zachary)

### c. Screening/Diagnostic

**UCI 11-30** Skin imaging with Technologies in Development (Kelly)

**UCI 13-13** Pilot study on in-vivo non-invasive skin imaging using multiphoton microscopy and multispectral imaging (Kelly)

**UCI 15-08** Spectral comparison between Spatially Modulated Quantitative Spectroscopy (SMoQS) and Polarization Sensitive Hyperspectral Multimode Dermoscopy for the purpose of skin compositional analysis (Kelly)

## II. Cutaneous Melanoma

### a. Screening/Diagnostic

**UCI 16-82** DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study #4 (Yamamoto)

**UCI 14-05** Multi-Center Evaluation of Oncogenesis via Spectral Analysis with the Melanoma Advanced Imaging Dermoscope (mAID) (Linden/Kelly)

### b. Metastatic: Unresectable Not Previously Treated

#### i. BRAF Mutated Only

**UCI 16-92**  
A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib versus Placebo plus Cobimetinib and Vemurafenib in Previously Untreated BRAF V600 Mutation-Positive Patients with Metastatic or Unresectable Locally Advanced Melanoma (Fruehauf)

**UCI 17-09**  
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma (Fruehauf)

**UCI 17-73\*\* Pending**  
A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors (Fruehauf)

#### ii. BRAF Wild-Type Only

**UCI 16-102\*\* Pending**  
A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced BRAFV600 Wild-Type Melanoma (Fruehauf)

### III. Cutaneous T-Cell Lymphoma (CTCL)

#### b. Screening/Diagnostic

##### **UCI 16-37\*\* Pending**

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome (Pinter-Brown)

#### a. Therapeutic

##### **UCI 16-45**

A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K  $\delta/\gamma$  inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma (Pinter-Brown)

##### **UCI 16-46**

A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects with Various Lymphomas and Leukemias (Pinter-Brown)

### IV. Miscellaneous & Phase 1 Clinical Trials

##### **ECOG-EAY131**

Molecular Analysis for Therapy Choice (MATCH) (Bota)

##### **UCI 16-96**

A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

##### **SWOG S1609**

(CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

##### **UCI 17-50\*\* Pending**

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

##### **UCI 17-58\*\* Pending**

Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas (Pinter-Brown)